Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDG-driven antifungal stewardship for empiric therapy in high-risk invasive candidiasis
2015-001566-26Phase 4Terminated
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of caspofungin, anidulafungin and liposomal amphotericin b in invasive candidiasis (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Duration of antifungal empirical therapy. Started Sep 2021; status: terminated.
02
Drugs
caspofunginanidulafunginliposomal amphotericin b
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on 2015-001566-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001566-26.